Drug Database
ME

meningococcal meningitis conjugate vaccine (Muinexi / CRM197 / MCV AC)

✓ Approved

CanSino Biologics · Cell-based Therapies · Cell-based Therapies

What is meningococcal meningitis conjugate vaccine?

meningococcal meningitis conjugate vaccine is a cell-based therapies developed by CanSino Biologics. It is approved for therapeutic indications via unknown.

Drug Profile

Brand NamesMuinexi, CRM197, MCV AC
CompanyCanSino Biologics
Drug ClassCell-based Therapies, Vaccine
RouteUnknown
StatusApproved

Therapeutic Indications

meningococcal meningitis conjugate vaccine is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Infections and infestationsMeningococcal bacteraemia✓ Approved

Related Research Articles

PubMedJournal of medical case reports2026-09-19

Like father, like daughter: amoxicillin-induced aseptic meningitis in a female patient and her father: a case report.

Farhood Ibrahim I, Seidel Sabine S, Kaeder Maximilian M, Schönlau Lars L et al.

Drug-induced aseptic meningitis (DIAM) is a neurological disorder that requires specialized diagnostic pathways and an in-depth patient history to prevent inaccurate diagnoses and unnecessary procedures. Amoxicillin has been reported as one of the drugs causing recurrent DIAM, with a total of 22 patients described in the literature. We report two cases involving patients of Mediterranean ethnicity -a father (69-years-old) and his daughter (47-years-old)-who presented to our neurology department at different time points with severe headache persisting for several days. Both patients disclosed recent use of amoxicillin to treat bronchitis and otitis. In both cases, examination of cerebrospinal fluid (CSF) revealed leukocytosis with lymphocytic predominance, while no causative pathogens were identified. After extensive investigations to rule out other causes of secondary headache, a diagnosis of amoxicillin-induced aseptic meningitis (AIAM) was established. Notably, the daughter experienced two similar episodes, both temporally associated with amoxicillin intake. Amoxicillin-induced aseptic meningitis is a rare adverse reaction that should be considered in patients presenting with severe headache in the absence of an identifiable pathogen. A thorough patient history combined with comprehensive diagnostic evaluation is essential to establish the diagnosis and to avoid unnecessary or excessive treatment. Additionally, potential genetic predispositions, as suggested in other forms of drug-induced aseptic meningitis, may play a role and should be considered in selected cases.

PubMedAAPS PharmSciTech2026-09-19

Comprehensive Stability Assessment of Squalene in a Nanoemulsion Adjuvant and the SpiN-Tec Vaccine: HPLC Quantification, Stress Testing, and Stability Studies.

Gomes Isabela Pereira IP, Rivelli Graziella Gomes GG, Bagno Flávia Fonseca FF, Hojo-Souza Natália Satchiko NS et al.

Squalene-based nanoemulsions are widely used as adjuvants in vaccine formulations, but their stability can be affected by environmental factors such as pH, oxidative stress, temperature, and light. We have produced a squalene nanoemulsion (CTVad1) to support the clinical development of new vaccines. This study aimed to develop and validate an HPLC method for squalene quantification in SpiN-Tec, a recombinant protein vaccine against COVID-19. We also aimed to evaluate the stability of the CTVad1 adjuvant and SpiN-Tec under controlled storage conditions. A reversed-phase HPLC method was developed and validated, and comprehensive forced degradation studies were performed on the raw material and SpiN-Tec under acidic, basic, oxidative, thermal, and photolytic conditions to demonstrate the stability-indicating capability of the method. Physicochemical, morphological, and biological characteristics were assessed, and stability studies of both the vaccine and the CTVad1 adjuvant were performed under accelerated and long-term conditions. The HPLC method was selective, precise, accurate, linear, and robust. Squalene raw material degraded under all tested conditions, whereas formulation in nano-sized globules improved its stability, with degradation observed only under hydrogen peroxide and light exposure. CTVad1 remained stable over time, exhibiting only minor, non-critical changes within the specification limits in both accelerated and long-term stability studies, regardless of the glass packaging used (clear or amber). In addition, the SpiN-Tec vaccine maintained its physicochemical and biological integrity under all tested conditions, with all evaluated parameters remaining within the established specification ranges. Our findings demonstrate that proper formulation, packaging, and storage conditions can preserve squalene stability in nanoemulsion-based vaccines, ensuring the quality, safety, and efficacy of the SpiN-Tec vaccine and its adjuvant throughout shelf life.

PubMedOcular immunology and inflammation2026-09-19

Bilateral Maculopathy in an Infant Following Measles, Mumps, Rubella, and Varicella-Zoster (MMRV) Vaccination.

Ben-Avi Ravid R, Amer Radgonde R

To report on the long-term clinical outcome of a healthy infant who presented with posterior uveitis following the administration of the combined measles, mumps, rubella, and varicella (MMRV) vaccine. Descriptive case report. A 13-month-old infant presented with bilateral visual loss two weeks after receiving the MMRV vaccine. Ophthalmic examination revealed bilateral retinitis and retinal vasculitis with exudative retinal detachment. Extensive infectious work-up was conducted including serologic exams and PCR testing of blood, aqueous humor, cerebrospinal fluid and urine. Serological tests for measles yielded positive IgM and IgG titers. PCR testing for measles in the aqueous humor and urine was negative. Neurologic assessment and neuroimaging were unremarkable, excluding central nervous system involvement. Empiric systemic antiviral and corticosteroid therapy was initiated. Gradual resolution of posterior uveitis ensued, culminating in bilateral macular scars. Over a six-year follow-up period, the patient demonstrated stable ocular findings with no evidence of recurrent inflammation or systemic autoimmune disease. Final visual acuity was 6/9 in each eye. This case represents a rare occurrence of non-necrotizing retinitis following MMRV vaccination. To our knowledge, this is the first report describing the sequential OCT characteristics of presumed measles vaccine-associated retinitis. The prolonged follow-up period supports the absence of an alternative etiology and provides valuable insight into the long-term course and visual prognosis of vaccine-associated retinopathy.

PubMedMedicine2026-09-19

Case report of successful conservative management of neonatal gastrointestinal perforation and intestinal stenosis.

Li Xiaoqing X, Tao Enfu E, Huang Huafei H

Neonatal gastrointestinal perforation (NGP) is a life-threatening condition requiring urgent intervention. While exploratory laparotomy remains the standard treatment, conservative management offers an alternative when surgery is not feasible. This case demonstrates the successful use of comprehensive conservative therapy in a high-risk infant with NGP and suspected intestinal stenosis. A 6-day-old, small-for-gestational-age male infant presented with vomiting, abdominal distension, and respiratory distress. Clinical deterioration led to the diagnosis of pneumoperitoneum, sepsis, and suspected necrotizing enterocolitis. NGP secondary to suspected necrotizing enterocolitis, with complications including septic shock, purulent meningitis, scrotal abscess, zinc deficiency, and malnutrition. Following parental refusal of laparotomy, conservative management was initiated, including peritoneal drainage, gastrointestinal decompression, broad-spectrum antibiotics, inotropic support, and parenteral nutrition. Nutritional support included zinc supplementation and gradual enteral feeding. The infant survived after 134 days of hospitalization, despite multiple complications. Long-term follow-up at 8 months revealed neurodevelopmental delays (developmental quotient 61), though physical growth was adequate with successful transition to complementary feeding. This case confirms that conservative management with peritoneal drainage and intensive multidisciplinary support can be a viable option for NGP, even in complex scenarios where surgery is not possible. It underscores the importance of vigilant monitoring, nutritional management, and awareness of potential long-term neurodevelopmental sequelae in such cases.

PubMedMedScience2026-09-19

Neoantigen cancer vaccines for gastrointestinal tumors: opportunities and challenges.

Zhao Zixuan Z, Du Xinyu X, Gao Xiaoliang X, Zhao Sheng S et al.

Gastrointestinal tumors are characterized by high global incidence and mortality rates. Although immune checkpoint inhibitors (ICIs) have achieved breakthroughs in some of these cancers, their overall response rate remains low. Neoantigen cancer vaccines have emerged as a promising new strategy for immunotherapy in gastrointestinal tumors due to their high specificity and strong immunogenicity. These vaccines effectively activate specific T-cell immunity and can produce synergistic effects when combined with ICIs. Various vaccine platforms offer distinct advantages, and clinical trials have shown encouraging potential in inducing immune responses and extending progression-free survival. Meanwhile, current challenges and future directions cannot be ignored. Key challenges primarily involve the accuracy of neoantigen prediction, tumor heterogeneity, and optimal treatment timing. Future directions include artificial intelligence (AI)-assisted multi-omics screening, the development of universal vaccines, optimization of novel delivery systems, and multimodal combination strategies. These advances are expected to promote the application of neoantigen cancer vaccines in postoperative recurrence prevention and early-stage treatment, ultimately moving toward personalized precision immunotherapy. This article systematically reviews the clinical progress and prospects of neoantigen cancer vaccines in treating gastrointestinal tumors, aiming to provide insights for immunotherapy in this field and offer new perspectives for further optimization of such vaccines.

PubMedFrontiers in oncology2026-09-19

Interim efficacy and preliminary survival outcomes of polatuzumab vedotin in combination for diffuse large B-cell lymphoma: a retrospective real-world study.

Liu Songshen S, Zhao Xia X, Shi Xue X, Xu Hong H et al.

The standard first-line R-CHOP regimen achieves cure in only approximately 50% of patients. Polatuzumab vedotin (Pola) is a novel antibody-drug conjugate targeting the B-cell receptor component CD79b; however, evidence regarding its real-world efficacy remains relatively limited. This retrospective study aims to evaluate the clinical efficacy of Pola in combination therapy. A retrospective analysis was conducted on 140 patients with complete clinical records treated at the Affiliated Hospital of Qingdao University between September 2022 and September 2025. Among them, 114 patients received combination regimens containing Pola, while 26 patients received regimens without Pola. Given the limited follow-up duration, this study primarily assessed interim efficacy, with preliminary survival data also reported. Among the 140 eligible patients, 4 deaths and 20 disease progressions occurred. The age range was 23-91, with a median age of 67; 45.0% were female. An ECOG performance status ≥2 was observed in 16.4% of patients, and 20.7% presented with B symptoms. Elevated LDH levels were found in 57.9% of patients. Ann Arbor stage III or IV disease was present in 65.0% of patients, and an IPI score >2 was recorded in 50.7%. Double-expressor lymphoma was diagnosed in 40.0% of cases. Bone marrow involvement was detected in 20.0% of patients, while 83.6% had lymph node extracapsular extension. Immunohistochemistry staining showed 36 patients (25.7%) with GCB subtype and 99 patients (70.7%) with non-GCB subtype. Median follow-up was 11 months (95% CI: 10.85-13.15). The objective response rate (ORR) was 94.4% in the Pola group and 70.0% in the non-Pola group (OR = 7.1, 95% CI: 2.0-27.2, P<0.001). Complete remission (CR) rates were 53.7% and 20.0%, respectively (OR = 4.6, 95% CI: 1.7-14.9, P = 0.002). The Pola group showed a statistically significant advantage in progression-free survival (PFS). Six-month PFS rates were 90.4% (95% CI: 84.8%-96.3%) for the Pola group and 76.9% (95% CI: 62.3%-94.9%) for the non-Pola group, while 12-month PFS rates were 87.2% (95% CI: 80.5%-94.6%) and 67.9% (95% CI: 51.7%-89.2%), respectively. Combination regimens containing Polatuzumab vedotin demonstrated a marked interim efficacy advantage, which may translate into potential long-term survival benefits.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about meningococcal meningitis conjugate vaccine